Cochlear share price on watch after COVID-19 profit collapse

The Cochlear Limited (ASX:COH) share price will be on watch today after reporting a collapse in profits because of the COVI9-19 pandemic…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Limited (ASX: COH) share price will be on watch on Tuesday following the release of its full year results for FY 2020.

How did Cochlear perform in FY 2020?

For the 12 months ended 30 June 2020, the hearing solutions company reported sales revenue of $1,352.3 million, which represents a 6% decline on a reported basis or 11% in constant currency. This revenue comprises Cochlear implants revenue of $817.9 million (down 3%), Services revenue of $395.5 million (down 7%), and Acoustics revenue of $138.9 million (down 20%).

Management advised that this decline was caused by difficult trading conditions in the second half because of COVID‐19‐related surgery deferrals. Cochlear implant unit sales fell 7% over the 12 months, having been up 13% during the first half.

On the bottom line Cochlear reported an underlying net profit after tax of US$153.8 million, which was down 42% year on year. This follows a collapse in its profits during the second half because of the aforementioned surgery deferrals. Second half profit fell 84% on the prior corresponding period.

On a reported basis, Cochlear recorded a net loss of $238.3 million. This includes $416.3 million in patent litigation expenses and $24.2 million in innovation fund gains after‐tax.

In light of the above, the company has unsurprisingly decided against declaring a final dividend in FY 2020.

Trading update.

Management advised that while elective surgeries have resumed, there is still a risk that second waves could result in new restrictions, complicating recovery plans and timing.

It also recognises that the surgeries currently occurring, particularly for adults and seniors, include a catch up of delayed surgeries from March to May. And while the majority of clinics have re‐opened, many are still running below capacity as they recommence operations carefully and follow social distancing disciplines.

As a result, the company expects there to be some impact on the number of patient assessments for cochlear and acoustic implants until clinic throughput normalises.

Nevertheless, the company's direct‐to‐consumer activities have been aimed at providing additional support to candidates, and potential candidates. It hopes these activities may assist in more quickly rebuilding the candidate pipeline once things normalise.

Outlook.

Due to the uncertain timing of a global recovery from the pandemic, management acknowledges that it cannot reliably estimate its FY 2021 revenues. As a result, it will not be providing guidance at this stage.

However, it intends to provide a trading update with its annual general meeting in late Octover.

Until then, the company "will be focused on market growth activities and strengthening our competitive position, while continuing to limit non‐essential spending until we have greater confidence in the outlook. There are a number of cost base considerations for FY21, which may be adapted if trading conditions materially change."

Looking further ahead, management is confident on the future prospects of the company.

It commented: "As we look to the future, we remain confident about the opportunity to grow our markets. There remains a significant, unmet and addressable clinical need for cochlear and acoustic implants that is expected to continue to underpin the long‐term sustainable growth of the business."

The company also notes that the arrival of telehealth solutions during the pandemic could be a big positive for its business.

"The pandemic has also driven the rapid adoption of telehealth and telemedicine which may lead to faster than expected structural changes in healthcare delivery. We experienced this first hand with the FDA fast‐tracking the approval of our Remote Check solution in the US."

"We have been investing in connected care solutions for many years and believe they provide the opportunity to open up access to our products and optimise outcomes for recipients by transforming the care model while delivering efficiencies to clinics," it added.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

asx share price boosted by us investment represented by hand waving US flag across winning athlete
Best Shares

Here are the best-performing ASX 200 shares since the US election result

We reveal the 10 ASX stocks that have had the highest share price gains since the US Presidential election.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face due to his ASX shares going up and in particular the Computershare share price
Share Market News

5 things to watch on the ASX 200 on Friday

A decent finish to the week is expected for Aussie investors.

Read more »

A smiling man at a shop counter takes payment from a female customer, with racks of plants in the background.
Best Shares

Here's why I think Wesfarmers shares are a great buy for any ASX investor

I argue that Wesfarmers offers investors both growth and income potential.

Read more »

A golfer celebrates a good shot at the tee, indicating success.
Share Market News

Here are the top 10 ASX 200 shares today

ASX investors finally enjoyed a win this Thursday...

Read more »

a man sits back from his laptop computer with both hands behind his head feeling happy to see the Brambles share price moving significantly higher today
Industrials Shares

Up 39% in a year, is there more growth to come for this ASX 200 share?

IML Equity Analyst Josh Freiman shares his views on a major ASX 200 industrial stock.

Read more »

Man looking at his grocery receipt, symbolising inflation.
Share Market News

What the latest US inflation print means for ASX 200 investors

The ASX 200 is likely to benefit if the US Fed cuts interest rates again in December. But will it?

Read more »

guy helping girl invest in shares and dividends
Opinions

5 ways for investors buying ASX shares to stay focused during economic uncertainty

AMP Chief Economist, Dr Shane Oliver, offers advice on how to handle the Trump factor.

Read more »

A worried man holds his head and look at his computer.
Share Fallers

Why Graincorp, Light & Wonder, Orica, and Wildcat shares are falling today

These shares are having a tough time on Thursday. But why?

Read more »